See more : Migom Global Corp. (MGOM) Income Statement Analysis – Financial Results
Complete financial analysis of KORU Medical Systems, Inc. (KRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KORU Medical Systems, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Global Health Limited (MEDANTA.NS) Income Statement Analysis – Financial Results
- Klondike Gold Corp. (KG.V) Income Statement Analysis – Financial Results
- Etablissements Maurel & Prom S.A. (MAU.PA) Income Statement Analysis – Financial Results
- Forward Science Corp. (7530.TWO) Income Statement Analysis – Financial Results
- Quadrise Fuels International plc (QFI.L) Income Statement Analysis – Financial Results
KORU Medical Systems, Inc. (KRMD)
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.52M | 27.90M | 23.49M | 24.18M | 23.16M | 17.35M | 15.98M | 12.29M | 12.25M | 11.24M | 8.70M | 7.76M | 6.39M | 4.92M | 3.77M | 3.44M | 2.35M | 1.73M | 1.75M | 1.56M | 1.53M | 1.66M | 1.76M | 2.09M | 2.07M |
| Cost of Revenue | 11.81M | 12.53M | 9.72M | 9.24M | 8.31M | 6.54M | 6.52M | 4.72M | 4.64M | 4.56M | 3.39M | 2.82M | 2.25M | 1.66M | 1.26M | 1.24M | 899.98K | 663.51K | 728.52K | 726.46K | 723.56K | 959.54K | 1.33M | 1.11M | 1.13M |
| Gross Profit | 16.71M | 15.37M | 13.77M | 14.94M | 14.85M | 10.81M | 9.46M | 7.57M | 7.60M | 6.69M | 5.31M | 4.94M | 4.14M | 3.26M | 2.51M | 2.20M | 1.45M | 1.07M | 1.02M | 833.76K | 804.83K | 697.02K | 427.94K | 978.94K | 939.85K |
| Gross Profit Ratio | 58.59% | 55.09% | 58.62% | 61.78% | 64.13% | 62.29% | 59.20% | 61.57% | 62.08% | 59.47% | 61.04% | 63.69% | 64.77% | 66.32% | 66.53% | 63.85% | 61.67% | 61.75% | 58.27% | 53.44% | 52.66% | 42.08% | 24.33% | 46.93% | 45.50% |
| Research & Development | 5.74M | 4.96M | 2.47M | 1.30M | 740.48K | 241.12K | 60.70K | 237.49K | 207.28K | 468.15K | 218.15K | 147.58K | 90.33K | 35.52K | 27.92K | 22.44K | 59.93K | 42.03K | 41.82K | 44.03K | 42.19K | 40.27K | 40.84K | 35.34K | 80.94K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.37M | 20.61M | 17.86M | 12.03M | 9.77M | 8.20M | 7.91M | 7.77M | 5.94M | 4.79M | 3.85M | 3.54M | 2.66M | 1.97M | 1.70M | 1.31M | 1.13M | 993.42K | 984.63K | 1.07M | 876.39K | 827.87K | 635.53K | 827.99K | 1.01M |
| Other Expenses | 870.39K | 0.00 | 679.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 26.98M | 26.15M | 20.80M | 13.74M | 10.85M | 8.75M | 7.97M | 8.31M | 6.42M | 5.54M | 4.30M | 3.88M | 2.85M | 2.07M | 1.79M | 1.42M | 1.25M | 1.09M | 1.11M | 1.19M | 1.05M | 949.57K | 802.20K | 1.08M | 1.18M |
| Cost & Expenses | 38.79M | 38.68M | 30.52M | 22.98M | 19.16M | 15.29M | 14.49M | 13.03M | 11.07M | 10.10M | 7.69M | 6.70M | 5.10M | 3.73M | 3.05M | 2.66M | 2.15M | 1.76M | 1.83M | 1.92M | 1.77M | 1.91M | 2.13M | 2.19M | 2.30M |
| Interest Income | 561.33K | 145.59K | 13.08K | 42.40K | 80.66K | 28.10K | 0.00 | 2.94K | 0.00 | 5.62K | 7.43K | 8.08K | 12.85K | 8.72K | 1.35K | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 3.41K | 512.00 | 4.55K | 28.28K | 31.54K | 36.39K | 47.50K | 51.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 870.39K | 587.14K | 463.13K | 418.60K | 340.23K | 309.26K | 308.71K | 300.61K | 271.57K | 283.88K | 232.96K | 190.97K | 103.98K | 65.77K | 64.80K | 79.36K | 68.20K | 60.43K | 79.09K | 81.82K | 80.55K | 81.44K | 84.84K | 84.97K | 87.80K |
| EBITDA | -9.40M | -10.19M | -6.57M | 1.61M | 4.34M | 2.37M | 1.88M | -474.20K | 1.42M | 1.36M | 1.24M | 1.25M | 1.42M | 1.30M | 774.76K | 855.89K | 261.71K | 38.29K | -9.16K | -277.54K | -165.09K | -171.12K | -289.42K | -17.38K | -149.54K |
| EBITDA Ratio | -32.96% | -36.40% | -27.84% | 16.71% | 33.36% | 18.94% | 11.22% | -3.52% | 11.79% | 12.78% | 14.35% | 16.25% | 22.00% | 26.37% | 20.87% | 24.96% | 11.15% | 12.28% | 4.55% | -17.79% | -7.44% | -10.33% | -14.12% | 5.54% | -26.45% |
| Operating Income | -10.27M | -10.78M | -7.03M | -1.25M | 585.68K | 1.16M | 1.48M | -736.25K | 1.18M | 1.15M | 1.01M | 1.06M | 1.29M | 1.19M | 721.52K | 779.01K | 193.51K | -22.14K | -88.25K | -359.35K | -245.64K | -252.56K | -374.26K | -102.35K | -237.34K |
| Operating Income Ratio | -36.01% | -38.65% | -29.93% | -5.19% | 2.53% | 6.71% | 9.29% | -5.99% | 9.65% | 10.20% | 11.58% | 13.68% | 20.17% | 24.28% | 19.11% | 22.65% | 8.24% | -1.28% | -5.06% | -23.03% | -16.07% | -15.25% | -21.28% | -4.91% | -11.49% |
| Total Other Income/Expenses | 496.40K | 105.71K | 665.09K | 60.52K | 110.74K | 12.41K | 85.18K | -40.45K | -38.81K | -72.86K | 2.78K | -24.29K | -7.97K | -1.71K | -59.06K | -54.16K | -193.51K | -232.59K | -129.56K | -40.14K | -31.53K | -14.84K | -11.24K | -2.11K | 237.34K |
| Income Before Tax | -9.77M | -10.68M | -6.36M | -1.19M | 696.42K | 1.18M | 1.57M | -776.70K | 1.14M | 1.07M | 1.01M | 1.04M | 1.28M | 1.19M | 662.46K | 724.86K | 0.00 | -254.72K | -217.82K | -399.49K | -277.17K | -267.39K | -385.50K | -104.46K | 159.46K |
| Income Before Tax Ratio | -34.27% | -38.27% | -27.09% | -4.94% | 3.01% | 6.78% | 9.82% | -6.32% | 9.33% | 9.56% | 11.62% | 13.37% | 20.05% | 24.25% | 17.55% | 21.08% | 0.00% | -14.68% | -12.48% | -25.60% | -18.13% | -16.14% | -21.92% | -5.01% | 7.72% |
| Income Tax Expense | 3.97M | -2.01M | -1.80M | 17.80K | 132.07K | 266.38K | 483.08K | -241.70K | 359.71K | 321.42K | 307.02K | 312.35K | 465.29K | 489.03K | -226.98K | -306.00K | 196.01K | 232.59K | 129.56K | 1.40K | 831.00 | 800.00 | 572.00 | 2.11K | -487.64K |
| Net Income | -13.74M | -8.66M | -4.56M | -1.21M | 564.35K | 910.57K | 1.09M | -535.00K | 782.86K | 753.12K | 703.43K | 725.76K | 815.89K | 704.09K | 889.44K | 1.03M | -2.50K | -254.72K | -217.82K | -400.89K | -278.00K | -268.19K | -386.08K | -104.46K | 250.30K |
| Net Income Ratio | -48.18% | -31.05% | -19.42% | -5.01% | 2.44% | 5.25% | 6.80% | -4.35% | 6.39% | 6.70% | 8.09% | 9.35% | 12.77% | 14.31% | 23.56% | 29.97% | -0.11% | -14.68% | -12.48% | -25.69% | -18.19% | -16.19% | -21.95% | -5.01% | 12.12% |
| EPS | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 45.60M | 45.00M | 44.39M | 41.93M | 38.78M | 38.13M | 37.87M | 37.83M | 37.99M | 37.63M | 36.66M | 36.01M | 34.25M | 36.24M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 20.63M |
| Weighted Avg Shares Out (Dil) | 45.60M | 45.00M | 44.39M | 41.93M | 39.06M | 38.92M | 38.39M | 37.88M | 37.99M | 37.63M | 36.66M | 36.04M | 35.10M | 36.85M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 23.12M |
KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate its...
KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients,...
KORU Medical Systems, Inc. (KRMD) Q1 2023 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Thomas Adams - Interim CFO, Secretary & Treasurer Conference...
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
KORU Medical Systems, Inc. Announces 2023 First Quarter Financial Results
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today...
KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today...
KORU Medical Systems, Inc. (KRMD) Q4 2022 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Hannah Jeffrey - Investor Relations Linda Tharby - President and Chief Executive Officer Tom Adams - Interim Chief Financial Officer Conference...
KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results, Accelerating to 19% Revenue Growth in 2022
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients,...
Source: https://incomestatements.info
Category: Stock Reports